
Gary M. Owens, MD
Articles by Gary M. Owens, MD











Specialty pharmaceuticals are currently the object of payer focus as one of the major drivers of increased pharmacy spending in 2014 and beyond.

Groundbreaking hepatitis C therapies represent a new era in treatment. But their cost is unprecedented, meaning health plans and PBMs are facing difficult formulary decisions.

As the FDA expedites approval of novel therapies, plans will need strategies to provide appropriate access while remaining observant of potential adverse events.





Prostate cancer is the most common solid organ tumor in men. According to the American Cancer Society, in 2013: about 238,590 new cases of prostate cancer will be diagnosed in the United States; about 29,720 men will die of prostate cancer.



Latest Updated Articles
Rethinking Heart Failure: Patient Classification and TreatmentPublished: November 10th 2022 | Updated:
The Changing Management of Prostate Cancer-Radium 223 Dichloride (Xofigo) Targets Bone MetastasesPublished: July 3rd 2013 | Updated:
Reflections on 2013-The First of the Breakthrough Therapies: A Payer PerspectivePublished: March 31st 2014 | Updated:
Hepatitis C: New Treatments Emerge in 2014 That Will Have Profound Implications for PayersPublished: March 31st 2014 | Updated:
New FDA Guidance on Biosimilars: Another Step Forward A Payer PerspectivePublished: May 30th 2014 | Updated:
Implications for Multiple Sclerosis in the Era of the Affordable Care Act: The Shifting Managed Care LandscapePublished: January 1st 2015 | Updated:



